General Information |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2023-01-24 |
| End date (estimated) |
2027-08-31 |
| Clinical feature |
| Label |
B-Cell Malignant Neoplasm |
| Link |
http://purl.obolibrary.org/obo/NCIT_C188021 |
| Description |
A clonal lymphoproliferative disorder composed of neoplastic B-cells. It includes B-cell non-Hodgkin lymphomas, B-cell leukemias, and plasma cell myeloma. |
|
Administrative Information |
| NCT number |
NCT05336409 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT05336409 |
| Other study identifiers |
| Name |
CNTY-101-111-01 (ELiPSE-1) |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT05336409 |
| Public contact |
| Email |
ntrede@centurytx.com |
| Public email |
ntrede@centurytx.com |
| First name |
Nikolaus |
| Last name |
Trede |
| Phone |
+1 888-506-7670 |
| Country |
|
|
| Sponsors |
Century Therapeutics, Inc.
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Recruiting |
| Estimated number of participants |
75 |
